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Testing the Noninferiority MarginsWe thank Messori et al. for their interest in our recent
systematic review of outcomes after implantation of
percutaneous left atrial appendage (LAA) occlusion
devices (1). The authors have used a novel statistical
analysis to raise the possibility that LAA occlusion
devices might be superior to newer oral anti-
coagulants (NOACs) in preventing stroke or systemic
embolism. This is potentially a thought-provoking
observation in favor of the efﬁcacy of the
percutaneous closure of the LAA.
The pivotal noninferiority randomized, controlled
trials like RE-LY (Randomized Evaluation of Long-
Term Anticoagulant Therapy), ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation), and ROCKET-AF (Rivar-
oxaban Once Daily Oral Direct Factor Xa Inhibitor
Compared with Vitamin K Antagonism for Preventionof Stroke and Embolism Trial in Atrial Fibrillation)
have tested whether individual NOACs were non-
inferior to warfarin in preventing stroke or systemic
embolism (2–4). The noninferiority margin in these
trials was derived from an earlier meta-analysis of
outcomes after administration of warfarin compared
with placebo (5). The noninferiority margin was set at
half the 95% conﬁdence interval of the estimated
effect of warfarin compared with placebo. Messori
et al. have used this methodology in a unique
quantitative-analytic framework to calculate the
difference in outcomes between LAA occlusion
devices and NOACs.
Although the superiority of LAA occlusion devices
over NOACs is a possibility, the analysis described
by Messori et al. is also somewhat provocative. We
agree that this is a very interesting hypothesis and
therefore would need to be veriﬁed in head-to-head
randomized, controlled trials before widespread
acceptability in clinical practice.Akhil Parashar, MD
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